News

Fierce Biotech2d
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...
Gilead to buy certain Hookipa Pharma assets for up to $10M
HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...
Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...
ascopubs.org3d
Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus–Negative, Locally Advanced Head and Neck Squamous Cell ...
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival Eligibility required untreated stage III-IVB HPV-negative HNSCC. Palbociclib 125 mg once ...